Efficacy and Safety of Niraparib as Maintenance Treatment in Patients With Extensive-Stage SCLC After First-Line Chemotherapy: A Randomized, Double-Blind, Phase 3 Study

Authors:

Abstract
No abstract available
Funding Information
  • AstraZeneca
  • Novartis
  • Bristol-Myers Squibb
  • Roche
  • Boehringer Ingelheim
  • Merck Sharp and Dohme United Kingdom
  • Pfizer
  • Science and Technology Commission of Shanghai Municipality (18DZ1910700, 18DZ1910702)

This publication has 29 references indexed in Scilit: